跳至主要内容
临床试验/CTRI/2023/08/056210
CTRI/2023/08/056210尚未招募4 期

Clinical utility and cost-effectiveness of pharmacogenomics-assisted treatment versus standard of care in patients with schizophrenia attending a tertiary care hospital in eastern India - Nil

Indian Council of Medical Research (ICMR)0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
4 期
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Adult (>=18 years) patients of both gender attending the OPD of Psychiatry, AIIMS, Kalyani, diagnosed with schizophrenia (DSM V), and are adjudicated by the treating psychiatrist to be treated with one or more of the following first-line antipsychotic medicine: olanzapine, risperidone, haloperidol, amisulpride, quetiapine, aripiprazole, and trifluoperazine

排除标准

  • Patients who are needed to be hospitalized or provided electroconvulsive therapy (ECT) at presentation, patients for whom any other antipsychotic drug is required to be initiated, and those who are unwilling to provide informed consent

研究者

发起方
Indian Council of Medical Research (ICMR)

相似试验